Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

Abstract

This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.

Keywords:

• biosimilars
• interchangeability
• rheumatoid arthritis

Acknowledgments

Stanley B Cohen and Mariah Z Leach are co-first authors for this podcast. The authors of this podcast manuscript meet criteria for authorship as recommended by the International Committee of Medical Journal Editors. The authors did not receive payment related to the development of this podcast. Andy Shepherd, PhD, of Envision Pharma Group provided writing and editorial support, which was contracted and funded by Boehringer Ingelheim Pharmaceuticals Inc. for these services. Boehringer Ingelheim was given the opportunity to review earlier talking points and the final transcript for medical and scientific accuracy, as well as intellectual property consideration.

Disclosure

SBC has received research grants from Abbvie, Amgen, BMS, Genentech, Lilly, Pfizer, Roche, and Sandoz and consulting fees from Abbvie, Aclaris, Amgen, Boehringer Ingelheim, Genentech, and Pfizer, and has received funding from Boehringer Ingelheim, study sponsor, as principal investigators of the VOLTAIRE-RA study. MZL has received consultancy fees from Abbvie, Boehringer Ingelheim, Center for Information and Study on Clinical Research (CISCRP), Digital Medicine Society (DiMe), Janssen, and Pfizer.